From Detection to Direction: Signatera MRD testing and its impact in CRC

Building the Evidence for ctDNA as a Surrogate Endpoint in Oncology Drug Development

Optimizing Breast Cancer Surveillance: A team approach with MRD testing

Leadership at Diagnosis: Quarterbacking the Path to Precision Care

Target, Track, Treat: Optimizing GI Cancer Management with Molecular Residual Disease Testing

New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform

ctDNA monitoring with Signatera: An overview for transplant providers

Tiny Traces, Big Impact: Changing the Paradigm in Breast Cancer Management with MRD Testing

Optimizing Patient Care in MIBC with MRD Testing, Real-world Clinical Cases

New Data Review Can treating molecular residual disease (MRD) in colorectal cancer improve outcomes

MRD Testing in NSCLC to Personalize Patient Care

Unlocking new uses for old drugs

a revolution in precision oncology using evidence-based MRD testing

New data: Optimizing breast cancer care and drug development with molecular residual disease testing

The Tipping Point: How clinically validated MRD testing is transforming patient management in colorectal cancer

Post ESMO review - How molecular residual disease testing is transforming cancer care

ASCO24 Summary: Latest data on ctDNA as a patient selection and early efficacy marker in drug development

Latest data on ctDNA as a patient selection and early efficacy marker for gynecologic cancers

How ctDNA can transform interventional trial design for GI cancers

Seeing the Forest Through the Trees: How tumor informed MRD testing can illuminate the treatment pathway in GI cancer

Review recently presented MRD data in colorectal and pancreatic cancer, exploring the potential impact on patient care